Cytokinetics Inc (NASDAQ: CYTK) has reported a loss for its fourth fiscal quarter (ending December 31) of $-1.26 versus a loss $-1.38 for the same period a year ago — a decline of -9%. For the latest four quarters through December 31, E.P.S. were $-5.26 versus $-5.45 for the same period a year ago — a decline of -3%.
Recent Price Action
On 2/27/25, Cytokinetics Inc (NASDAQ: CYTK) stock increased 1.3%, closing at $47.45. However, trading volume in this advance was below average at 78% of normal. Relative to the market the stock has been weak over the last nine months but has risen 2.3% during the last week.
Current PriceTarget Research Rating
Cytokinetics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment